Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure | Kmieciak et al. Journal of Translational Medicine 2011 9 35 http content 9 1 35 TRANSLATIONAL MEDICINE RESEARCH Open Access Tumor escape and progression of HER-2 neu negative breast cancer under immune pressure 11 2 2 3 4 Maciej Kmieciak Kyle K Payne Michael O Idowu Margaret M Grimes Laura Graham Maria-Libera Ascierto Ena Wang4 Xiang-Yang Wang5 Harry D Bear3 and Masoud H Manjili1 Abstract Background Emerging data from pre-clinical and clinical studies suggest that HER-2 neu-specific T cell responses could induce HER-2 neu antigen loss in the tumor cells. These data suggest that patients with HER-2 neu negative breast cancer might have had HER-2 neu positive premalignant lesions in the past that progressed to HER-2 neu negative breast cancer under HER-2 neu-specific immune pressure. Methods We conducted a pilot study in patients with HER-2 neu positive and HER-2 neu negative breast cancers as well as a patient with ductal carcinoma in situ DCIS . HER-2 neu expression was determined by FISH. HER-2 neu-specific T cell responses were determined by using IFN-y ELISA. Expression of IFN-y Ra in the tumors was determined by immunohistochemistry analysis of paraffin-embedded tissues. Results We determined that majority of 10 of 12 patients with HER-2 neu negative breast cancer had HER-2 neu-specific IFN-y producing T cell responses which was stronger than those in patients with HER-2 neu positive tumors. Such immune responses were associated with nuclear translocation of IFN-y Ra in their tumor cells. Patient with DCIS also showed HER-2 neu-specific T cell responses. Conclusion These data suggest that conducting retrospective studies in patients with HER-2 neu negative breast cancers and prospective studies in patients with HER-2 neu positive DCIS can determine whether HER-2 neu negative invasive carcinomas arise from HER-2 neu positive DCIS under the immune pressure. Introduction In recent years there has been emerging evidence from both .
